Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions

This is a phase 2 crossover, randomized, placebo-controlled, single-blind, repeat dose study in PBH subjects to determine the effect of mizagliflozin on adverse events and postprandial glucose excursions.

Inclusion Criteria:Roux-en-Y gastric bypass surgery performed > 6 months prior to enrollmentDiagnosis of PBHExclusion Criteria:History of current medical conditions (other than PBH) which may result in hypoglycemia such as insulinoma, adrenal insufficiency, insulin autoimmune hypoglycemia, congenital hyperinsulinemia.Current use of insulin or insulin secretagoguesHistory of current fasting hypoglycemiaPregnancy and/or lactation: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 2 weeks after participating in the study